Department of Microbiology, PathWest Laboratory Medicine Western Australia, Fiona Stanley Hospital, Murdoch, WA, Australia; Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, WA, Australia.
Public Health Emergency Operations Centre, Department of Health, East Perth, WA, Australia.
Pathology. 2022 Apr;54(3):344-350. doi: 10.1016/j.pathol.2021.11.006. Epub 2022 Feb 10.
SARS-CoV-2 viral load declines from the time of symptom onset; in some studies viral load is higher or persists longer in more severe COVID-19 infection, and viral load correlates with culture positivity. This was a retrospective cohort study of inpatients and outpatients during the first wave of COVID-19 infection in Western Australia, March to May 2020, of the relationship of SARS-CoV-2 viral load (using the First WHO International Standard for SARS-CoV-2 RNA) from symptom onset, by clinical subgroups determined from the public health database and hospital records, using regression analysis. We studied 320 samples from 201 COVID-19 cases: 181 mild, seven severe, 11 critical, and four cases who died (two were also critical cases). At symptom onset the mean viral load was 4.34 log IU/mL (3.92-4.77 log IU/mL 95% CI, cobas SARS-CoV-2 assay ORF1a Ct 28.9 cycles). The mean viral load change was -0.09 log IU/mL/day (-0.12 to -0.06 95% CI). R was 0.08 and residual standard deviation 2.68 log IU/mL. Viral load at symptom onset was higher for those reporting fever compared to those not reporting fever. Viral load kinetics were not different for gender, age, shortness of breath, or those requiring oxygen. Mean viral load at usual release from isolation at 14 days was 2.5 log IU/mL or day 20 was 1.8 log IU/mL. Variability in respiratory sample SARS-CoV-2 viral load kinetics suggests viral loads will only have a role supporting clinical decision making, and an uncertain role for prognostication.
SARS-CoV-2 病毒载量从症状出现时开始下降;在一些研究中,COVID-19 感染更严重的患者病毒载量更高或持续时间更长,病毒载量与培养阳性相关。这是一项回顾性队列研究,纳入了 2020 年 3 月至 5 月西澳大利亚 COVID-19 感染第一波期间的住院患者和门诊患者,研究了 SARS-CoV-2 病毒载量(使用世界卫生组织首次发布的 SARS-CoV-2 RNA 国际标准)与症状出现时间的关系,通过公共卫生数据库和医院记录确定的临床亚组进行回归分析。我们研究了 201 例 COVID-19 病例中的 320 份样本:181 例轻症,7 例重症,11 例危重症,4 例死亡(其中 2 例也是危重症)。在症状出现时,平均病毒载量为 4.34 log IU/mL(3.92-4.77 log IU/mL 95%CI,cobas SARS-CoV-2 检测 ORF1a Ct 值为 28.9 个循环)。平均病毒载量变化为-0.09 log IU/mL/天(-0.12 至-0.06 95%CI)。R 值为 0.08,剩余标准差为 2.68 log IU/mL。与未报告发热的患者相比,报告发热的患者病毒载量更高。性别、年龄、呼吸急促或需要吸氧的患者病毒载量动力学无差异。14 天通常隔离释放时的平均病毒载量为 2.5 log IU/mL,第 20 天为 1.8 log IU/mL。呼吸道样本 SARS-CoV-2 病毒载量动力学的变异性表明,病毒载量仅在支持临床决策方面具有作用,而在预测方面的作用不确定。